Stanford inventors have identified a treatment regimen that allows expansion of cardiomyocytes (CMs) derived from human induced pluripotent stem cells in vitro.
Heart rhythm disorders are difficult to treat with conventional drug therapy and intraoperative injury to the cardiac conduction system (CCS) complicates heart-related surgeries and is a major cause of morbidity and mortality.